NM
INDV icon

Newtyn Management’s Indivior Pharmaceuticals INDV Stock Holding History

Newtyn Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61M Sell
2,000,000
-534,538
-21% -$17.7M 6.51% 6
2025
Q4 		$90.9M Sell
2,534,538
-1,665,462
-40% -$50.9M 9.55% 2
2025
Q3 		$101M Buy
4,200,000
+1,592,982
+61% +$33.3M 12.4% 1
2025
Q2 		$38.4M Buy
2,607,018
+956,080
+58% +$11.1M 5.82% 6
2025
Q1 		$15.7M Buy
1,650,938
+244,407
+17% +$2.57M 2.49% 14
2024
Q4 		$17.5M Buy
1,406,531
+538,426
+62% +$5.54M 3.04% 12
2024
Q3 		$8.46M Buy
+868,105
New +$10.2M 1.3% 23

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Newtyn Management's INDV Position: Q1 2026 in Review

Newtyn Management reduced its Indivior Pharmaceuticals (INDV) stake by 21% in Q1 2026, selling an estimated $17.7M and leaving 2,000,000 shares worth $61M. The position accounts for 6.51% of the portfolio, ranked #6.

Newtyn Management first reported a position in INDV in Q3 2024 and has held it in 7 quarters since. The position peaked at $101M in Q3 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Newtyn Management held 2,000,000 shares of Indivior Pharmaceuticals worth $61M as of Q1 2026.
  • Newtyn Management sold 534,538 Indivior Pharmaceuticals shares in Q1 2026, an estimated $17.7M.
  • Indivior Pharmaceuticals made up 6.51% of Newtyn Management's portfolio in Q1 2026, its #6 holding.
  • Newtyn Management first reported a position in Indivior Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Newtyn Management's Indivior Pharmaceuticals position peaked at $101M in Q3 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Newtyn Management's 13F filing for Q1 2026, filed 15 May 2026.